A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies

Trial Profile

A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs AZD 5991 (Primary)
  • Indications Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Jun 2018 Planned End Date changed from 12 Aug 2019 to 23 Oct 2019.
    • 26 Jun 2018 Planned primary completion date changed from 12 Aug 2019 to 23 Oct 2019.
    • 24 Oct 2017 Planned End Date changed from 26 Aug 2019 to 12 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top